ucsf logo

Flavio G. Vincenti, MD

Transplant Nephrology • Pancreas Transplant Surgery
Portrait of Flavio G. Vincenti
Portrait of Flavio G. Vincenti
ucsf logo

Flavio G. Vincenti, MD

Transplant Nephrology • Pancreas Transplant Surgery

On this page

About me

Dr. Flavio Vincenti is a specialist in kidney and pancreas transplantation. He came to UCSF Medical Center in 1975 for a fellowship in transplant nephrology and was appointed a member of the kidney transplant team.

In 1978, Vincenti co-authored an article in the New England Journal of Medicine on the role of blood transfusions in improving kidney transplants. He also wrote a series of articles on the complications of transplants and has been a leading investigator and writer on the use of anti–interleukin 2 receptor monoclonal antibodies, used to reduce the chance of organ rejection. In addition, he is a proponent of minimizing immunosuppressive drugs after transplants.

Vincenti is a member of many professional organizations, including the Transplantation Society, American Society of Nephrology, American Society of Transplantation and International Society of Nephrology. He is a co-leader of the Immune Tolerance Network's kidney section. In addition, he is on the editorial boards of Graft and the American Journal of Kidney Diseases.

Education & training

Board certification

  • Nephrology, American Board of Internal Medicine/Nephrology
  • Internal Medicine, American Board of Internal Medicine

Internship

  • Nephrology, American University of Beirut Medical Center

Degree

  • MD, American University of Beirut

My expertise

Please check with your health insurance plan regarding coverage for this type of care. Not all providers at UCSF Health are covered by every insurance plan.

For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.